Skip to content

IL17 in Systemic Lupus Erythematosus Patients: Association With Disease Activity and Organ Damage

IL17 in Systemic Lupus Erythematosus Patients: Association With Disease Activity and Organ Damage

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05045417
Enrollment
140
Registered
2021-09-16
Start date
2021-10-01
Completion date
2022-04-30
Last updated
2021-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosus

Brief summary

Many laboratory markers can be measured for assessment of Lupus activity as aberrant manufacturing and imbalance of the cytokines of T-helper cell which already have been implicated within autoimmunity pathogenesis as IL-18 and IL-10 levels are usually elevated in lupus sufferers and correlated with SLEDAI score IL-17 has been linked to immune-mediated organ damage in several autoimmune diseases and recently it has been linked to pathogenesis of a murine model of lupus and human lupus Diverse cytokine abnormalities which common in lupus patients may skew T cells differentiation into IL-17-producing CD4+ and double negative T cells. This could promote the autoimmune process by activation of immune cells &stimulation of proliferation of B-cell and production of antibody

Interventions

DIAGNOSTIC_TESTSerum level of IL-17

Measurement of serum level of IL-17 : 1. To explore the role of IL-17 in systemic lupus erythematosus 2. To determine the relation between IL-17 and lupus disease activity 3. To analyze the correlation between IL-17 and internal organ affection (lupus nephritis , interstitial lung disease)

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* SLE will be diagnosed according to the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE * Age ≥ 18 years. * Patients who are able and willing to give written informed consent

Exclusion criteria

-Any other autoimmune disease rather than SLE. - * Systemic diseases * Malignancy * pregnancy

Design outcomes

Primary

MeasureTime frameDescription
SLE disease activity index (SLEDAI)18 Months• Assessment of the disease activity in the patients will be done by using the SLE disease activity index (SLEDAI). It potentially measures reversible manifestations of the underlying inflammatory disease process. The scale includes24 weighted attribute grouped into 9 domains. The final score is the sum of all attributed scores. * No activity 0 * mild activity: 1-5 * moderate activity: 6- 1 0 * high activity : 1 1 - 1 9 * very high \> 20

Countries

Egypt

Contacts

Primary ContactAya M Ahmed, assistant lecturer
aya.ali1@med.sohag.edu.eg01013325505
Backup ContactFaten E Mohamed, professor
01066881548

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026